Journey Medical (DERM) to Release Earnings on Monday

Journey Medical (NASDAQ:DERM) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $12.05 million for the quarter.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The company had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.21 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Journey Medical Price Performance

Shares of DERM stock opened at $7.03 on Monday. The stock has a market capitalization of $162.42 million, a price-to-earnings ratio of -7.48 and a beta of 0.86. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical has a twelve month low of $3.20 and a twelve month high of $7.84. The stock has a fifty day simple moving average of $6.15 and a two-hundred day simple moving average of $5.36.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DERM shares. Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a report on Thursday, March 27th. Industrial Alliance Securities set a $10.50 price objective on Journey Medical in a research note on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $9.88.

Insider Activity

In other Journey Medical news, CEO Claude Maraoui sold 14,905 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now owns 2,052,418 shares of the company’s stock, valued at approximately $10,282,614.18. This trade represents a 0.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 105,831 shares of company stock worth $536,622. Insiders own 13.16% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.